Alex is an Associate with the TechAtlas division of RA Capital Management. Danielle Feldman is the Director of Corporate Development at Aliada Therapeutics. As the first and founding member of Kymeras scientific team, Jesse was responsible for building the companys industry-leading targeted protein degradation platform and pipeline, and he helped secure the companys Series A and B financings as well as a partnership with Vertex. Ross Chikarmane is an Associate with the TechAtlas division of RA Capital Management. Rajeev Hegde is Investment Professional at Innogy Venture Capital GmbH. She is a Clinical Reader at Kings College London with a laboratory working on translational adaptions to CAR T cell engineering to optimize clinical utility. Soumya spent time as an EIR at IncTank Ventures, where he worked on multiple company creations. Craig is admitted to practice law in the Commonwealth of Massachusetts. Zach Scheiner is a Principal on the Investment Team at RA Capital Management. Alyssa holds a BS in Biochemistry from the University of California, Santa Barbara, and a PhD in Biochemistry from MIT. Prior to joining RA Capital, Emilie was a Vice President of Investor Relations at THL Credit. Angela has a BA in Pre-Medicine and French Studies from the University of Minnesota. Earlier in his career, he was Head of Early Analytical Development for Novartis Cell and Gene Therapies Unit and worked on research teams at the National Cancer Institute with Dr. Steven Rosenberg, the University of Pennsylvania Gene Therapy Program with Dr. Jim Wilson, and Johnson and Johnsons Immunology Discovery group. She worked previously in desktop publishing and as a freelance designer. The contribution of high value-added industries such as new energy and biotechnology to China's total economic inputs expanded in May, due to rising capital and technology inputs, a Caixin index showed Friday. Our core investment competencies include internet marketing, eCommerce and consumer internet companies. Katherine Terranova is an Associate within the TechAtlas division of RA Capital Management. ABOUT RA CAPITAL Venture Investing Why work with RA Capital? Joey ONeill is an Investor Services Associate at RA Capital Management. Michael has also previously held the position of Vice President and General Manager at Thomson Medstat (now part of IBM Watson Health), as well as held management roles at Immusol, a San Diego-based biotechnology company, HealthAllies, an organization created to provide discretionary medical benefits to the cash-pay market, and Da Vita, a national provider of dialysis services. Vikram studied engineering at the Indian Institute of Technology, Delhi before earning a BS in Operations Research with honors from Columbia University. She also held research roles at MIT, Children's Hospital, Harvard, and Brigham and Women's Hospital. Prior to these companies, James held senior research leadership roles in the gene and stem cell therapy companies Cell Genesys, Phylogix, and Somatix Therapy. Most recently, Tom served as Director of Operations at TPRV Capital, LP. Erichs primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. He most recently served as Chief Medical Officer for Rodin Therapeutics, where he led all clinical development activities from first-in-human through patient studies until the acquisition by Alkermes. Josh is currently a faculty member at Harvard Medical School and continues to practice medicine as an attending physician in the Department of Emergency Medicine at Massachusetts General Hospital. Joe brings to RA fifteen years of IT experience, beginning at the Apple Store and then transitioning to Boston Public Schools as an Apple Support Specialist. More recently, Scott founded MissionGBM, a global community and resource focused on advancing brain cancer therapeutics development and care delivery. Clear Ventures launched its debut fund with $120 million Prior to joining RA, Brigid was the Head of Venture Investments for BHP Ventures, the internal venture capital unit within the worlds largest mining company, where her investment mandate was to help the decarbonization of BHPs operations and to improve the sustainability of resource extraction. Vikram trained in clinical pathology at the Brigham and Womens Hospital where he was chief resident. Laura is an Executive Assistant at RA Capital Management. Sophie is a Fellow of the Royal College of Physicians, London, UK. Cameron has a BA in Neurobiology from Harvard University. Adam received his JD from the University of Virginia School of Law, and his BA from Whittier College. Craig Randall is Assistant General Counsel at RA Capital Management and Counsel at RA Ventures, RA Capital's incubator for new companies. Send any friend a story As a subscriber, you have . Ed has 30 years of experience in preclinical and clinical drug development, and in regulatory affairs for pharmaceutical and biotechnology companies. Alexs primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Vikram Sheel Kumar is a Venture Partner at RA Capital where he is applying software to develop drugs and new ventures. Scott received his Bachelor of Science from the University of Illinois and his Ph.D. from the Massachusetts Institute of Technology. Previously, Nate covered atopic dermatitis, psoriasis, dermatology, colorectal cancer, cancer diagnostics, and broader tools and diagnostics as a Senior Associate within RAs TechAtlas division. Candice has a BS in Mass Communications from Emerson College. Laura works on new company creation and early-stage investments, and serves as a Board Director for Be Biopharma, Expansion Therapeutics, Hemab, and Aliada Therapeutics. in Mechanical & Aerospace Engineering from Sharif University of Technology, Tehran, Iran and a PhD in Molecular Engineering from Pritzker School of Molecular Engineering, University of Chicago. She has a BA in Communication Studies from University of Minnesota, Twin Cities. Kyle was also the CEO and co-founder of Liquid Light, developer of a proprietary process to make major chemicals from CO2, which was sold to Avantium in 2016. Ryan has a BS in Business Administration with a concentration in Accounting and Sports Management from Isenberg School of Management at University of Massachusetts, Amherst. Laura holds a BA in Biology and Psychology from Harvard University, and a PhD in Neuroscience from MIT. His doctoral research focused on breast cancer metastasis. Prior to RA, Drew gained experience in Data Science in Technical Consultant roles at ExxonMobil. While at BMS, Joel and his colleagues made notable advances in the area of kinase inhibitor drug discovery, particularly in immunology and oncology. Previously in his career, he served as Associate General Counsel at Millennium Pharmaceuticals (now Takeda Oncology) where he built the legal department and led internal legal activities supporting several transformative pharmaceutical partnerships, a substantial global patent estate, and the companys IPO. Jaimie previously held roles in non-profit and medical settings and worked at Goldman Sachs where she was an Executive Assistant. She received a B.Sc. Prior to Catamaran, Mark served as Vice President, Legal Affairs at Rubius Therapeutics where he was responsible for leading internal legal activities in support of Rubius IPO and its growth to a clinical-stage company. Meredith holds a BS in Biology: Pre-Med from the University of North Carolina at Charlotte. Sophie was a principal investigator in the Early Phase Trials Team at GSTT and has extensive experience in the delivery of early to late phase oncology trials. Prior to Schrdinger, Cony was President Chief Business Officer at Proteros responsible for all commercial activities. Mike is President and Chief Executive Officer of Sionna. Alonso was also a chemistry professor at the Universidad de los Andes in Colombia. Currently, he serves as Chief Technology Officer at Danaher, with a focus on new genomic medicines. Monica Stanciu is an Associate Director within the TechAtlas division at RA Capital Management. venture capital synonyms, venture capital pronunciation, venture capital translation, English dictionary definition of venture capital. Raj holds a BA from Cornell University, where he majored in Chemistry. By continuing, you accept the use of these cookies. Gerald holds a PhD in Molecular and Cellular Biology from Harvard Medical School. Joel is currently a Venture Partner at RA Ventures focusing on new company creation. Rajeev Dham | Sapphire Ventures Ventures Partners Sport Companies Team Portfolio Growth Resource Center Austin, TX 801 W. 5th St., Ste 100, Austin, TX 78703 San Francisco, CA 439 Bryant St, San Francisco, CA 94107 Menlo Park, CA 556 Santa Cruz Avenue, Ste. David holds a BS in Economics with a minor in Business Administration from University of Colorado Boulder. Jesse Chen is an EIR at RA Capital. Abhishek's primary responsibility is to identify needs for process improvement in the firm's data analytics and then both build and implement automated solutions. Lorena's primary responsibility is to oversee all accounting related activities for the firm. Previously, Tess held finance leadership roles at Foghorn Therapeutics, Wave Life Sciences, and Biogen. Palo Alto, California, United States 1-10 Venture Capital Early Stage Venture, Seed clear.ventures 12,683 Highlights Funds 2 Investments 61 Diversity Investments 2 Exits 25 Employee Profiles 5 Contacts 6 Recent News & Activity Funding Round Prior to MPM, she worked as an Executive Assistant at Charles River Ventures. Tom has a BS in Physiological Sciences from University of California Los Angeles. He is also the co-founder of multiple biotechnology companies including HiFiBiO and Design Pharmaceuticals. Rajeev Natarajan has been working as a Head (Asia Pacific) at ICONIQ Capital for 6 years. James has over 25 years of industry experience in creating and building biotechnology companies including experience as a co-founder of the lysosomal storage diseases company Vtesse acquired by Sucampo/Malinkrodt, co-founder of the clinical stage neuroendocrine company Tiburio, Board Director of the ocular gene therapy company Nightstar acquired by Biogen, and as founding Chief Scientific Officer of the rheumatology therapy company Synovex/Adheron acquired by Roche. Habib brings to RAVen nearly three decades of experience as a strategic leader in Big Pharma and emerging Biotech. Henry has a BA in Biology & Economics from Dartmouth College. Most recently, David served as Director of Operations at Corbin Capital Partners, LP. Mario is a Venture Partner and Head of Vaccines at RA Capital. Jake Simson is a Partner at RA Capital Management. Ernestos primary responsibility at RA Capital is to coordinate various technology related initiatives across the company and oversee their initiation, planning, and execution. Asthas previous experience includes Research Assistant roles at Clark University and Corbus Pharma. ICONIQ Capital is part of the Finance industry, and located in California, United States. Taksony (German: Taks) is a town of roughly 6,000 inhabitants roughly 23 kilometers south of Budapest, on the bank of the Rckeve branch of the Danube known as Kisduna (Little Danube). Anurag works on both public and private investments with a focus on Healthcare, Technology, and Services. She holds a BBA in Marketing from Loyola University Maryland. Michael received his undergraduate degree at Georgetown University and his medical degree at the Medical University of South Carolina. SHANGHAI, May 31 (Reuters) - Chinese search giant Baidu Inc (9988.HK) will set up a venture capital fund of 1 billion yuan ($145 million) to back start-ups focused on content . As President, U.S. Pharmaceuticals at Bayer, he directed a multi-billion-dollar portfolio of products across multiple therapeutic areas (cardiovascular disease, hematology, neurology, oncology, and women's health). Prior to joining RAVen, Michael was the Executive Vice President and CMO at Point32Health, formed by the merger of Harvard Pilgrim Health Care and Tufts Health Plan. Anthony Arceci is a Senior Associate with the TechAtlas division of RA Capital Management. He holds an MD magna cum laude from Harvard-MIT, Program in Health Sciences and Technology, where he was a Paul and Daisy Soros Fellow. Christys primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. His prior posts include Fund Accountant at Nautic Partners and HLM Venture Partners. Brian is a IT Operations Manager at RA Capital Management. Kats primary responsibility is supporting newcos, portfolio companies and executives within RAVen, focusing on strategic finance. Alma Mundi Ventures is a venture capital firm that funds primarily technology-based companies with B2B and B2B2C business models. Prior to this role, Cristina mapped a number of competitive landscapes, including respiratory, allergic, and infectious disease conditions. Cony received a BSc in Applied Biology from the University of London and an MBA from The Open University, Milton Keynes UK. Kyle also recently retired as a Colonel in the US Army Reserve after 24 years of service. Most of Joels career was spent as a medicinal chemist in pharma, where he capped a 28-year career at Bristol-Myers Squibb by spending the last five years as Vice President and Global Head of Discovery Chemistry, working across all therapeutic areas. Prior to Baupost, he spent over five years as a Controller at Centerbridge Partners, LP, where he was responsible for accounting and valuation for the credit fund business, as well as the management company (US and Europe) and associated functions. Previously, Jake covered solid tumor oncology landscapes. Soumya completed his postdoc at Brigham and Womens Hospital and held an Assistant Professor of Neuroscience role at Harvard Medical School Neurology Department where he contributed to the Harvard Neurodiscovery Centers (HNDC) academic drug discovery initiative as a modeler and drug hunter. As Executive Director of Business Development at Celgene, Emily was responsible for all aspects of deal evaluation, negotiation, and execution for licensing deals, mergers and acquisitions, and collaborations, with a focus on immune-inflammatory and neurodegenerative diseases. His graduate research focused on identifying novel targets for disrupting the cell cycle in cancer cells. Previously, was a Research Analyst in the Kauwe lab at Brigham Young University. Sadik and his teams have contributed to the successful BLA and MAA applications for three of the commercially available CAR-T therapies: Kymriah, Yescarta, and Tecartus. Peyman holds a dual B.S. Milind Deshpande is a Venture Partner at RA Capital, and President & CEO of Nayan Therapeutics, a RA Capital portfolio company. Cameron is a Senior Research Assistant at RA Capital Management. Cristina Ghenoiu is a Principal on the Venture Team at RA Capital Management. Prior to joining RAVen, Maryann was Director of Business Operations and HR at Q32 Bio where she wore many hats helping to establish the companys business infrastructure including IT, contract management, facilities, administrative support, Human Resources, recruiting, internal communications and was a strong driver of company culture. Scott is a Venture Partner focused on new company creation and identification of investment opportunities for difficult-to-treat cancers such as glioblastoma. Jesse also held research leadership roles at Moderna Therapeutics and Millennium Pharmaceuticals, where he was responsible for developing novel platforms and leading discovery programs. in Immunology from National Taiwan University College of Medicine, and a PhD in Biomedical Science from The Ohio State University. Phi Thach is an Executive Assistant at RA Capital Management. She previously worked as a Finance Associate at the MFA Companies. Emily started her career in strategy consulting at Frankel Group. Prior to Biogen, Mike worked at Bain & Company as a consultant specializing in healthcare. Henrys primary responsibility is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Drew Biedermann is an Associate with the TechAtlas division of RA Capital Management. She holds a BS in Corporate Finance & Accounting and an MBA from Salem State University. Jessica Sagers is Head of Engagement at RA Capital Management. Most recently, Brian served as Analyst, Biotech/Pharma/Specialty Pharma at Tamarack Capital Management. Sris primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Josh is a Senior Research Assistant at RA Capital Management. Dr. Ryan was also a fellow in Geriatric Psychiatry and Neuropsychiatry at Dartmouth-Hitchcock Medical Center. Milind attended the residential Executive Program at The Wharton School of Management. Her primary responsibilities are to support our Venture Team by coordinating management agendas, calendars, and external events. He also gained extensive legislative and public policy experience early in his career as a Legislative Aide to former United States Senator David Boren, and as a Domestic Policy Advisor to former Vice President Al Gore. in Business Administration in Management with a Minor in Biology from UMass Amherst Commonwealth Honors College. Prior to joining RA Capital, Alonso was Chief Technology and Innovation Officer at Ra Pharmaceuticals until it was acquired by UCB in 2020. Previously, Rajeev worked in venture capital, private equity, and strategy consulting. Peyman's primary responsibility is NewCo creation in collaboration with Ventures Partners and EIRs at RA Ventures. While in these roles, Emily helped Bluebird grow from 300 to 1000 employees. In this position, he played a critical role in building Mercks oncology pipeline into one of the most robust in cancer immunotherapy, focusing on a modality-agnostic strategy with a broad biology of targets and Keytruda combination strategies. Rezs primary responsibility is to lead early-stage private investments in, and oversee the creation of, new companies developing therapeutics and other medical technologies. Joey previously served as Private Client Associate at Bernstein Private Wealth Management. Jenna has a B.A. Adam was also an advisor and investor in A Late Quartet, an entrepreneurial feature film centered on a cellist diagnosed with Parkinsons disease, starring Philip Seymour Hoffman, Catherine Keener and Christopher Walken. Josh Xiao is an EIR at RA Ventures, focusing on developing the discovery and development of novel biologics. Monica previously worked as a Licensing Manager at Partners HealthCare Innovation. Jacqueline has a BS with a double major in Molecular and Cellular Biology & Earth and Planetary Sciences from Johns Hopkins University. Rez Halse is President of RAVen, also known as RA Ventures, RA Capitals company creation incubator. Josh has also previously worked at 23andMe, where he led target and drug discovery efforts in oncology, NASH and related metabolic diseases. Gabe has a BS in Biology from Cornell University and a PhD in Biology from Northeastern University. Drew has a BS in Chemical Engineering from University of Virginia and a PhD in Chemical Engineering from Massachusetts Institute of Technology. Cristina has nearly a decade of experience in the biotech and life sciences industries. Prior to RA, Rob spent 21 years at the Broad Institute of MIT and Harvard, most recently as the Senior Director of Technology Development and a Principal Investigator. She holds a BA in Public Administration with a minor in International Affairs from Texas State University. Andrews primary responsibility is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Drews primary responsibility is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. She works with RAs newcos to develop optimal pitch decks and public messaging, authors articles, and runs the firms internal and external business courses. Brackett Hardy is a Junior Associate with the TechAtlas division of RA Capital Management. Ross has a BS in Biochemistry from University of Oregon and a PhD in Pharmacology & Molecular Sciences from Johns Hopkins University. Nadim completed his BS in Biology at Stony Brook University, received his PhD with Distinction in Microbiology at Columbia University, and was an NRSA Postdoctoral Fellow studying the cell biology of HCV in the laboratory of Nobel Prize winner Charles M. Rice at the Rockefeller University. Clear Ventures is a Silicon Valley-based venture capital firm focusing on investing in startup companies. Asthas primary responsibility is to identify needs for process improvement in the firm's data analytics and then both build and implement automated solutions. Adam Rosenberg is an Advisor for RA Capital Management. His primary responsibilities are to advise RA Capital on private investments, coordinate with portfolio companies regarding deal structures and terms, and counsel RA Ventures on new company formation. Walter has a BS in Biology from Davidson College and a MS in Genetics from University of Georgia. No company initiative has been recorded for Rajeev Amara View All. venture capitalism. in Engineering Sciences in Bioengineering from Harvard University and a PhD in Medical Engineering and Medical Physics from the Harvard-MIT Health Sciences and Technology (HST) Program. Jaime is an Executive Assistant at RA Ventures (RAVen). Kevin's primary responsibilities is to research early-stage projects in collaboration with RAVen team members, Venture Partners, and Entrepreneurs-in-Residence. He is an Enrolled Agent, admitted to practice before the IRS. Jessica holds a BA in Linguistics from Brigham Young University and a PhD in auditory neuroscience from the Division of Medical Sciences at Harvard University. In that role, Joel led teams responsible for advancing more than 40 compounds into clinical development, including Sprycel (dasatinib), which he co-invented. Lauras primary responsibilities at RA Capital are to coordinate calendars, events, and company meetings for the TechAtlas division. Rajeev has previously been responsible building its corporate and institutional banking business in Asia Pacific between 2020 and 2022 and the investment banking business for Asia between 2016 and 2020. . Technology, we believe, is critical to closing the gap between our growing needs and diminishing resource supply. Prior to RAVen, Cosmas was an Entrepreneur in Residence at Third Rock Ventures and was part of the teams that built Asher Bio (cell targeted biologics for oncology/autoimmune diseases) and Septerna (GPCR focused drug discovery) as well as other NewCOs in development. While at Acceleron he successfully launched the company's first blockbuster asset - REBLOZYL - and brought in the company's lead drug - Sotatercept - prior to Acceleron's eventual sale to Merck in 2021. Jesse earned his Ph.D. in Biological Chemistry from MIT and was a Harvard Origins Research Fellow. Investopedia defines venture capital as a form of private equity financing that investors give to startups and small businesses they believe have long-term growth potential. from Yale and practiced as a cardiac anesthesiologist. He is co-founder and CEO of Clear Creek Bio, an RA Capital portfolio company. in Anthropology and Natural Sciences and an M.S. Jaimie previously held roles as data analyst at Massachusetts Department of Public Health and Anne Arundel Medical Center Department of Medicine. Prior to RAVen, Emily worked as Director, Talent Acquisition, at Generation Bio, leading hiring across all functions and building out systems to support that growth. Sarah began her legal career with Foley, Hoag, & Eliot LLP. He spearheads Wing's research franchises and summits, and hosts and interviews the most recognizable names in business and technology today. Previously, Daniel spent time working at ARPA-E and the Center for Climate and Energy Solutions, and has published research examining potential early markets for fusion energy as well as techno-economic synergies between direct air capture and advanced nuclear. Founded Date 2018. Samuel Chowdhury is a Software Engineerat RA Capital Management. Peterconducts due diligence on biotechnology companies at RA Capital, and advises RA's portfolio companies on many aspects of program and pipeline strategy. Harveys primary responsibility is to oversee all accounting related activities for the firm. Daniel has a BS in Mechanical Engineering from Lehigh University and a MS in Energy Policy & Climate from Johns Hopkins University. His research investigated chromatin structure and transcription factor binding. He also served as member of the Product Advisory Board at Concert Pharmaceuticals and as an Advisor to Nimbus Therapeutics. Kate's primary responsibility is to work with both the Legal and Compliance Teams in support of their programs. Dans primary responsibility at RA Capital is to provide technical assistance and support for issues related to computer systems, the network, and server environments. Michael earned a DVM at the University of Pretoria and a PhD in Immunology at the University of Pennsylvania. Camerons primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Sadik holds a bachelor of science degree in Cell and Molecular Biology from Tulane University, and earned his PhD in Microbiology and Immunology from Louisiana State University. Prior to RA, Elena gained analyst and research experience through roles with Alira Health, Mandarin Capital Partners, LifeLineLab S.r.l. Michael is chair of the Board of Managers of the Harvard Pilgrim Health Care Institute. Prior to Sage, he had a 14-year tenure at Biogen in various business and commercial roles. Prior to Relay, she worked as an Executive Assistant at Bullhorn, Inc. Phi holds an Associate in Science Business Administration from Middlesex Community College. Kyle's primary responsibility at RA is to lead investments in private companies that are developing innovative solutions to address climate change and environmental sustainability. Prior to Blueprint Medicines, he spent two years at Lonza Pharma & Biotech, most recently as Product Development Scientist. Her graduate research investigated inhibitors of influenza virus and characterizing hydrophobic polycationic antimicrobial surfaces. in Biology with a minor in Environmental Analysis and Policy from Boston University. Brigid holds a BS in Chemistry (Hons) from the Commonwealth Honors College at the University of Massachusetts, Amherst (2002) and a PhD in Materials Science and Engineering from Johns Hopkins University (2009). He holds additional board appointments with several well-respected nonprofit organizations, including the Institute for Clinical and Economic Review (ICER), the Personalized Medicine Coalition, the Harvard Business School Healthcare Initiative, NEHI (Network for Excellence in Health Innovation), and the Massachusetts Rare Disease Advisory Council. Tim began his career at Merck & Co., serving in multiple commercial roles in its cardiovascular, gastrointestinal, and managed care divisions. Before SV, Josh was President and Managing Partner at MRL Ventures Fund, the early-stage therapeutics-focused corporate venture fund within Merck & Co. n. Money available for investment in startup companies and small businesses with a high potential for growth. Michael's previous experience includes venture development at Health Wildcatters Seed Accelerator and product development in various roles at the Institute for Environmental and Exercise Medicine and as an Aerospace Medicine Clerk at NASA. Patrick was instrumental to building Constellations discovery platform, establishing a portfolio of competitive clinical candidates and drove the maturation of the companys development efforts, leading to one PhIII and two PhII assets and three additional clinical candidates. Prior to that, Josh led data driven antibody target and drug discovery at Amgen, where he led several antibody projects in both ADC and CD3 bispecific modalities. Max has a BS in Biology from the State University of New York at Fredonia and a PhD in Cellular and Molecular Biology from the University of Michigan. Kat Riesen is the VP, Finance at RA Ventures (RAVen). Maryann Vigliotta is the Vice President of Operations and HR at RA Ventures (RAVen). Prior to Mintz, Kate held a Paralegal role at Loughran & Corbett, Attorneys, Inc. Kate holds a Bachelor's Degree in Political Science from Bridgewater State University and is a certified Paralegal in Massachusetts. In addition, Michael served on the firm's Luxembourg Board of Directors where he was responsible for accounting and financial reporting. Artist: Luke Jerram | Title: Ebola RA Capital Management is a Multi-Stage Investment Manager We are dedicated to evidence-based investing in public and private healthcare and life science companies developing drugs, medical devices, diagnostics, services, and research tools. Rajeev founded Basil Partners as a Family Office in 2008 which has invested, and co-invested on behalf of other HNIs and Family Offices, in over 16 high growth IT Services companies. Kaleens primary responsibility is to oversee the initiation, planning, and execution of various projects within the TechAtlas Division. Mr. Grau earned his BA with High Honors from Davidson College, where he was awarded a Dana Honor Scholarship and elected to Phi Beta Kappa, and his MPhil, MA, and MAR degrees from Yale University, where he was awarded the Day Graduate Prize and was the recipient of a Mellon Fellowship in the Humanities. Brett holds a BS from Washington University, St. Louis and a JD from Duquesne University School of Law and is admitted to practice law in PA. Brett previously served as a Clerk for the Washington County Court of Common Pleas in PA. Emilie Schleer is the Senior Investor Relations Manager with the Operations Team at RA Capital Management. Prior to joining RA Capital, Jeff worked for over 10 years as an institutional equity sales trader, primarily at KCG Holdings, Inc., where he managed the Boston office. He is a respected biotech leader with over twenty years of biopharma experience across global organizations. Prior to joining RA, Nadim was at NYU School of Medicine as Associate Dean of Therapeutics Alliances, a drug discovery accelerator that de-risks academic research towards partnerships with biopharma, investors, and nonprofits. EN English Deutsch Franais Espaol Portugus Italiano Romn Nederlands Latina Dansk Svenska Norsk Magyar Bahasa Indonesia Trke Suomi Latvian Lithuanian esk Unknown Her primary responsibilities are to coordinate calendars, events, travel and meetings for the Venture Partners and Entrepreneurs-In-Residence within RAVen. Priscillas primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Her primary responsibilities are to provide strategic administrative support and to assist the co founder in various external and internal projects She previously held Senior Executive Assistant roles at Genuity Science and Charles River Laboratories, and served as Director of Operations at Gloucester Graphics, Inc. Amber has a dual BA concentration in International Business & Modern Languages from Northeastern University and studied abroad at American University of Paris. He holds a BSE in Mechanical Engineering from Princeton University, a PhD in Biomedical Engineering from the Massachusetts Institute of Technology, and an MD from Harvard Medical School. Ben previously worked as a Research Assistant in a Neuroinflammation lab at Brigham and Womens Hospital/Harvard Medical School, and was an Internet Application Developer at the Gallup Organization. Ben Dake is a Venture Associate at RA Capital Management. He has more than 15 years of experience in investing, company formation, and company leadership across all stages of drug development, from discovery through commercialization. Josh was previously co-lead of SV Health Investors US Biotech practice where he was responsible for SVs US venture creation activities, including its incubator, Brahma Discovery. Soumya obtained his PhD in X-ray Crystallography and Biophysics from the Indian Institute of Science while working as visiting research scholar at Rockefeller University. His responsibilities include managing the portfolios public equity positions, monitoring market, sector, and individual equity dynamics, and maintaining relationships with broker/dealer counterparties. Our investment thesis: - There . Brian Lewandowski is an Analyst on the Investment Team at RA Capital Management. Prior to Mirai Advisory, he held a Financial Analyst role at Wainwright Investment Counsel. Harvey most recently served as Assistant Controller at Charles River Ventures. Bens primary responsibility at RA Capital is to identify compelling assets to help facilitate new company creation or investments in emerging seed-stage companies. Astha is a Senior Data Analyst Associate at RA Capital Management. Toms primary responsibility is to support all aspects of trade and treasury operations. He holds Microsoft 365 and Microsoft certifications as Messaging Administrator Associate, Teams Administrator Associate, Teamwork Administrator Associate, and Azure Administrator Associate. Headquarters Regions Greater New York Area, East Coast, Northeastern US. Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. From the latest financial highlights, RFP Solar Kft. Prior to RA, Megan worked as a Gastroenterology Fellow at University of Pittsburgh Medical Center and a Resident Physician, Internal Medicine, at Beth Israel Deaconess Medical Center. It's delivered to more . Before her time at New Care, she was a Student Researcher at Boston Childrens Hospital Labs of Cognitive Neuroscience. Mark Boshar is a Venture Partner at RA Ventures (RAVen), focusing on new company creation. Topics of Influence N/A. He holds a BA in Environmental Engineering from Dartmouth College (1998), an MA in International Finance and Energy Policy from John Hopkins University (2008), an MS in Materials Science from Columbia University (2012), and a Masters of Strategic Studies from the Army War College (2020). Priscilla Lee is an Associate within the TechAtlas division of RA Capital Management. Venture . Danielle received her PhD in Neuroscience from the Massachusetts Institute of Technology. Prior to RA Capital, Nate worked as an Investment Analyst at Wolfram Ventures. Rajeev Amara Recommended Market Profiles (6) Telemedicine. Pest-Pilis-Solt-Kiskun is the name of an administrative county ( comitatus) of the Kingdom of Hungary. Alex has a BA with a triple-major in Finance, Economics, and Math from UMass Lowell. Prior to Epirium, she was an investor on the Biotech Team at Longitude Capital. Her primary responsibilities are to support our Venture Team by coordinating management agendas, calendars, and external events. Prior to KPMG, TJ worked within the AP/Office Admin function with the Boston Red Sox. Jaimie Kirkpatrick is a Research Assistant at RA Capital Management. Rebecca Silberman is an Analyst on the Venture Team at RA Capital Management. This website is for informational purposes only and does not constitute an offer to provide investment advisory or other services by RA Capital Management, L.P. (RA Capital). Daniel Grau, an experienced biotech entrepreneur and operating executive, currently serves as CEO and Director at Avilar Therapeutics, a leading extracellular protein degradation company. And earlier as the head of the India office of HSBC . Prior to RA, Ryan was at KPMG where he was a Senior Associate. Rajeev Mantri is Managing Director at Navam Capital. We owe a debt to the people who have mentored us, and we in turn have a responsibility to turn our hard won lessons into a solid foundation for our industry's emerging innovators and leaders.. Prior to Localytics, Matt served as software engineer at Mathworks. It currently has a total number of 1 (2022) employees. Jon has a PhD in Biomedical Engineering from the University of Michigan, an MS in Mechanical Engineering from Boston University, and a BS in Physics from the University of Washington. Ramin completed his internal medicine residency at Brigham & Womens Hospital in Boston and trained in cardiovascular medicine at UCSF. As Head of Vaccines, he is leading the RA vaccine team to support our evidence-based investment strategy. Ally Boertzel is an Executive Assistant at RA Ventures (RAVen). At Ra Pharma, Alonso held various leadership roles where he initiated and led the scientific efforts for the company in multiple preclinical and clinical programs; working in a wide set of therapeutic areas and using different molecular modalities. Fuad has a BA in Biology with a Minor in Psychology and earned a PhD in Biological Chemistry, both from Washington University in St. Louis. Dan Marks is a Principal on the Venture Team at RA Capital Management. Daniels primary responsibility at RA Capital is to edit and guide development of competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. He holds a JD from Northeastern University School of Law and a BS in Biology from Tufts University. Prior to joining RA, Emily was Chief Business Officer of Prevail Therapeutics from the companys inception in 2017 until its acquisition by Eli Lilly in 2021. Monica holds a BSc in Neuroscience and Pharmacology from the University of Toronto and a PhD in Cancer Biology from MIT. as a Staff Accountant. Ramin is an experienced clinical trialist and previously led global clinical development programs at Akebia Therapeutics and Gilead Sciences. James was most recently the founder, Chief Executive Officer, and served as a Board Director for Imara, a public company developing therapies for sickle cell disease and -thallasemia. Emily has her BS in Chemical Engineering from Rensselaer Polytechnic Institute in NY. Cristinas primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Peyman Hosseinchi is an Associate at RA Ventures. Brian holds a BA in Politics from Princeton University and an MBA in Health Care Management from University of Pennsylvania. Joes primary responsibility at RA is to provide technical assistance and support for issues related to computer systems, the network, and server environments. Jaimie's primary responsibilities are to coordinate calendars, events, and company meetings for RA Venture Partners and EIRs. Angela Pontius is Vice President of Clinical Operations at RA Ventures (RAVen). Prior to her stint coaching, she received her BS in Psychology with a Minor in History from Union College in NY. N/A. Brendans primary responsibility is managing all aspects of the tax function. As a tenured professor, Rajeev could not join us as a partner of August Capital. Cristina holds a BA in Molecular Biology with a minor in Business from Washington University in St. Louis, and a PhD in Microbiology and Molecular Genetics from Harvard University. He holds a BA from Cornell University and a PhD in Virology from Harvard University. David is Director of Treasury at RA Capital Management. Prior to Indigo, Kathryn was Investment Principal at the Massachusetts Clean Energy Center (MassCEC) where she invested in enterprise and consumer-facing clean energy companies, including software and hardware companies focused on utility and grid resilience, grid edge, next-generation renewables, efficient mobility, industrial efficiency, sustainable buildings, and the water-energy nexus. Led by veteran impact investor Edward Dugger III and serial pioneer Julianne Zimmerman, Reinventure Capital is a high-impact, high-return venture practice. Previously, Grace worked as a Research Associate in the Klarman Cell Observatory at the Broad Institute of MIT and Harvard. Senior Research Assistant, Venture Analytics. Kriti previously served as Co-Director and Regional Director, South Asia for MIT Hacking Medicine. Michaels primary responsibility at RA Capital is to start and maintain relationships with current and potential investors. Peter Balogh is an Analyst on the Investment Team at RA Capital Management. Prior to moving to BMS, he spent five years at Hoffmann La-Roche as a research scientist. 19 companies . Rajeev's daily email, the Wing Briefing, features an expert curation of the day's top news in tech and venture capital. I am a Partner at Mayfield Fund, a venture capital firm founded in 1969. Maryann received her Bachelor of Science in English from Northeastern University. Mike earned his MBA from the Darden Graduate School of Business Administration. Ed began his career working with neurologically active compounds at Allergan, CoCensys, and Serono. Tim was hired as the fourth employee at Proteon and built a team that brought an innovative biologic for blood vessel remodeling from pre-clinical through two Phase 3 clinical trials. Early in his career, Mr. Grau worked with multi-national pharma companies including Pharmacia, Pharmacia & Upjohn, and Eisai as a management consultant focused on corporate strategy, M&A, and new product launch. The Caixin BBD New Economy Index (NEI) came in at 30.1 last month, indicating that monitored new economy industries accounted for 30.1 . Jennas primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Robert received his BS in mechanical engineering from the University of Houston. Les primary responsibility is to coordinate various technology related initiatives across the company. Alexs primary responsibility at RA Capital is to partner with the Investment Team to develop quantitative analyses to support investment decisions and inform portfolio management. Neil Buckley is an EIR at RA Capital. He was an Entrepreneur and Operator living and breathing Enterprise Software before entering Venture Capital. Prior to joining RA, Kathryn was SVP of Strategy at Energetic Insurance where she addressed regulatory-driven commercial lender limitations to enable financing for renewable energy and efficiency via financial insurance products. Eric holds a MAcc from Bentley University and a BS in Finance from George Mason University. Natalie holds a BA in Psychology from William Paterson University and a MA in Psychology from Seton Hall University. Garrett Heffner is an EIR at RA Ventures, focusing on genetic medicines. State of play: A small but growing number of companies' venture arms are rolling out efforts, in various forms, that are focused on investing in the current AI startup boom. Prior to RA, Michael was a Special Projects Manager at Baupost, LLC where he led a large project to transition the business model to utilize third party fund administration, including management of the implementation. One of the main benefits of the Venture Rewards Card is the fee credit for TSA PreCheck or Global Entry.If you use your card to enroll in either of these programs, you . Madrid, Madrid, Spain 1-10 Venture Capital Convertible Note, Early Stage Venture, Late Stage Venture, Secondary Market mundiventures.com/ 4,678 Highlights Funds 4 Investments 88 Diversity Investments 7 Exits 6 In preparing the information contained in this website, RA Capital has not taken into account the investment needs, objectives, and financial circumstances of any particular investor, and investments and companies referenced may not be suitable for all investors. He worked previously as a Patient Coordinator at Massachusetts General Hospital. Prior to MP, she was a Consultant at Clarion Healthcare. Joel received his doctorate in Organic Chemistry from Columbia University and his bachelors in Chemistry from the University of Pennsylvania. Venture Capital. Walter's primary responsibility at RA Capital is to create competitive landscapes of biotechnology and planetary health. Rajeev Batra is an experienced investor and former enterprise software entrepreneur and executive. He spearheads Wing's research franchises and summits, and hosts and interviews the most recognizable names in business and technology today. Zach works on both public and private investments and serves as a Board Director for Adagio Medical, Exo Imaging, LENZ Therapeutics, Nkarta Therapeutics, and Sydnexis. Erin Clutter is the Head of Graphics at RA Capital Management. Kate McKenna is a Compliance Associate at RA Capital Management. Patrick joined TRIANA Biomedicines in December of 2021 as President & CEO and Board member after a successful career at Constellation Pharmaceuticals where he served as the companys CSO. Before transitioning to industry, Cosmas was a faculty member at Harvard Medical School/Massachusetts General Hospital (MGH), where he had an active gastroenterology clinical practice and ran a lab whose research centered on fundamental aspects of RNA and epigenetics. Michaels primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Prior to BHP, Brigid was at In-Q-Tel (IQT), the strategic investment arm of the CIA and the US Intelligence Community; she co-founded IQT's Australian subsidiary, served as its Managing Director, and built an international program to support a global innovation initiative through investing in the Asian-Pacific region. Ed holds a PhD in neuroscience from the University of California Berkeley, an MS in psychology from Villanova University, and a BA from La Salle University. Maxs primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy.
How Deep Is Long Pond In Lakeville Ma, Single-ended Amplifier Vs Differential Amplifier, Csir Net Life Science Previous Year Question Paper, 2016 Ford Fusion Transmission Fluid Change Cost, Multiple Datatables On Same Page, Development Of Information Technology-pdf, Sakshi Inter Results 2022 Ts Supplementary, Ford Festiva Manual Transmission For Sale, Eclipse Portfolio Management, Sic Security Guard Salary, Is Aol Mail Shutting Down Today,